Alta Sciences

FEBRUARY 19, 2025

Researchers must characterize the anti-drug-antibody (ADA) response in preclinical and clinical studies and report any ADA-positive samples as a risk-based approach. These interactions may disrupt protein function, trigger immune responses, or contribute to other toxicological risks.

Drug Development 52

Drug Development Clinical Pharmacology Immune Response Drugs 52

Codon

NOVEMBER 3, 2024

Even after microbiologists discovered the bacterium that causes the illness in 1882, it wasn’t until the 1920s that researchers were able to develop a vaccine for TB. Chilean research participants aged 15 to 35 who received the vaccine during a case-control study , for example, only showed a 10 percent reduced risk of pulmonary TB.

Vaccine 98

Vaccine Trials Therapies Treatment 98

Drug Target Review

APRIL 26, 2023

Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs. The study appears in Nature Biotechnology.

RNA 98

RNA Medical Schools Engineering Disease 98

Broad Institute

JULY 11, 2024

Reporting in Science , researchers at Massachusetts General Hospital and the Broad Institute of MIT and Harvard have made a surprising discovery about these drugs. They found that mIDH1 inhibitors trick the tumor cells into thinking they are infected with a virus, causing the immune system to mount an antiviral response.

Treatment 72

Treatment Immune Response Drugs Virus 72

Broad Institute

JUNE 27, 2024

There are currently no treatments, but researchers from the Whitehead Institute for Biomedical Research and Broad Institute of MIT and Harvard have developed an approach that could one day be used to turn off the gene encoding this protein throughout the brain to treat or even prevent prion disease.

Disease 142

Disease Therapies Clinical Trials Engineering 142

Drug Target Review

JUNE 6, 2023

Natural killer (NK) cells are another immune cell type that, as the name suggests, also have potent cell-killing activity, and have a well-known role in the anti-tumour immune response. In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Drug Target Review

DECEMBER 7, 2023

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. In bacteria , cGAS-like cyclases are central parts of the CBASS immune response.

RNA 59

RNA Immune Response DNA Molecular Biology 59

The Pharma Data

OCTOBER 25, 2020

German drugmaker CureVac said preclinical studies of its COVID-19 vaccine candidate, CVnCoV, showed the vaccination prompted a successful immune response. The messenger RNA-based vaccine, which is designed to block replication of the coronavirus, was shown to induce neutralizing antibodies and activate T-cells in hamsters and mice.

Vaccine 52

Vaccine Immune Response RNA Clinical Trials 52

DrugBank

MAY 15, 2024

Researchers would sift through natural extracts , hoping to stumble upon a compound that exhibited beneficial effects. In fact, it's one of the most exciting areas in drug research today. With billions in funding and innovative research, we're starting to see strategies that can tackle these tough targets.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98

The Pharma Data

MARCH 8, 2022

SARS-CoV-2 viruses can hide from recognition by the immune system. However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections. Researchers led by Prof. Camouflage protects virus from immune system. Samira Marx, Beate M.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

Codon

DECEMBER 12, 2024

Among the report’s authors are 16 members of national academies, two Nobel Laureates, and several researchers who have previously been frontrunners in the quest to create mirrored life. ” 1 Now, it seems, these researchers have changed their minds. 4 As far as we know, right-handed proteins never occur naturally.

DNA 104

DNA RNA Vaccine Virus 104

Drug Target Review

FEBRUARY 7, 2024

How does the Artificial Intelligence (AI) system developed by the research team contribute to understanding the interactions between SARS-CoV-2 viral protein fragments and the immune system? Such peptides play a critical role in the machinery for amplifying innate immune responses. The study was published in PNAS.

RNA 69

RNA Virus Immune Response Engineering 69

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. Half of the recovered COVID-19 patients studied had T cell responses to highly networked epitopes identified by the research team.

Vaccine 52

Vaccine Virus Research Immune Response 52

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection.

Vaccine 52

Vaccine Immune Response Virus RNA 52

Drug Target Review

OCTOBER 2, 2024

Early-phase clinical trials have shown the safety and efficacy of using stem cells for cardiac repair, encouraging further research and development. RNA-based therapies, including mRNA and RNA interference (RNAi), are being explored to modulate gene expression in heart cells.

Therapies 98

Therapies Disease Engineering RNA 98

The Pharma Data

DECEMBER 14, 2020

Supported by promising phase 1 data, CureVac announced Monday that it has enrolled the first participant in the pivotal phase 2b/3 study of its messenger-RNA based coronavirus vaccine, CVnCoV. The company announced positive phase 1 trial results in November that demonstrated its candidate elicited immune responses and was well-tolerated.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

DECEMBER 8, 2020

Overall, the vaccine protected against symptomatic disease in 70% of cases, according to a team led by researchers from Oxford University in England. ” Previous clinical trials of the vaccine had found that the vaccine triggers antibody and T-cell immune responses, and is safe in people aged 18 and older. TUESDAY, Dec.

Vaccine 52

Vaccine Trials Immune Response RNA 52

DrugBank

MARCH 12, 2025

Introduction Messenger RNA (mRNA) technology has emerged as one of the most significant medical breakthroughs. Once delivered into the body, the mRNA instructs cells to produce these antigens, which are then presented to the immune system. Another challenge is the potential for unintended immune responses.

Vaccine 52

Vaccine Treatment Clinical Trials Therapies 52

Dark Matter Blog

JULY 16, 2021

As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Growing up in Shrewsbury, Massachusetts, it was natural for me to attempt to get a summer job up the road at the Worcester Foundation for Biomedical Research, where the first oral contraceptive was created. I wanted to use molecular biology to create drugs.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

The Pharma Data

JULY 18, 2021

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease.

Disease 52

Disease Immune Response Vaccine FDA Approval 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Dynavax is also advancing CpG 1018 as an advanced vaccine adjuvant through research collaborations and partnerships. CHENGDU, China , Feb.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

SEPTEMBER 30, 2021

. “We used NanoSTING because the adjuvant for intranasal vaccination and single-cell RNA-sequencing to verify the nasal-associated lymphatic tissue as an inductive site upon vaccination. The nasal vaccine also will serve to equitably distribute vaccines worldwide, consistent with the researchers.

Vaccine 52

Vaccine Disease Immune Response Virus 52

Drug Target Review

APRIL 3, 2024

Could you share an example of a specific project or research that you have worked on and the impact it has had in your field? We continue our research to gain further insights into the underlying biology of GDF-15 and its role in cancer pathogenesis and treatment resistance. in North America) in late 2017.

Science 105

Science Clinical Development Treatment DNA 105

The Pharma Data

JUNE 26, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Drug Target Review

JULY 11, 2023

In the quest to combat and eradicate diseases, scientists and researchers are increasingly turning to the immense potential of artificial intelligence (AI) as a tool. In this way, the platform inverts the traditional target-led discovery process, and allows the immune system to guide us to the most importantdisease modifying target.

Disease 75

Disease RNA Small Molecule Clinical Development 75

The Pharma Data

MAY 17, 2021

Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. 14, 2020 ). The mRNA candidate is currently being assessed in a phase 1/2 study.

Vaccine 40

Vaccine Immune Response RNA Virus 40

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. This collaboration brings together Sanofi Pasteur’s leadership in vaccines and Translate Bio’s mRNA research and development expertise.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 21, 2021

market specifically target the spike protein to prevent transmission, explained Dr. Kathryn Edwards, scientific director of the Vanderbilt University Vaccine Research Program in Nashville. “The height of the antibody response may be somewhat proportional to how sick you are in the beginning. “The spike is really critical.

Vaccine 52

Vaccine Virus Immune Response RNA 52

Codon

SEPTEMBER 29, 2024

But, regardless of which was first, they all operated with the same core data as their mechanism for understanding life: messenger RNA ( mRNA ). The lab created a plan with eight research institutions across three continents. Models of life became the dominant research paradigm in nearly every life-sciences field.

Engineering 140

Engineering Virus DNA Therapies 140

Broad Institute

AUGUST 11, 2022

A team led by researchers at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Research at MIT has discovered and characterized one of these unexplored microbial defense systems. In the new study, the researchers wanted to know if the proteins work the same way in prokaryotes to defend against infection.

DNA 52

DNA Virus Immune Response Bioinformatics 52

Codon

AUGUST 27, 2024

Identifying a new or unexpected pathogen quickly, particularly when it occurs in conjunction with other, more common illnesses, is a key challenge for doctors, researchers, and public health professionals concerned with disease preparedness and biosecurity. Cite: Allison Berke. “Defense-Forward Biosecurity.” DOI: [link]

DNA 99

DNA Laboratories Hospitals Virus 99

LifeSciVC

JULY 1, 2024

So when I was asked recently to share advice to a group of undergraduate students doing research at Penn State, I was drawn to the idea of connecting scientific principles to some life lessons. The central dogma of molecular biology is that information generally (with few exceptions) flows from DNA to RNA to Protein.

Science 86

Science Immune Response Molecular Biology RNA 86

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

Drug Target Review

FEBRUARY 5, 2024

Dr Ashley Seifert, an associate professor in the Department of Biology at the UK College of Arts and Sciences, and his research group have pioneered the use of spiny mice and other animal models to understand how complex tissue can regenerate, bridging regenerative biology and medicine. The Innate Immune Response to Infection [Internet].

Laboratories 59

Laboratories Immune Response RNA Regulations 59

The Pharma Data

OCTOBER 25, 2020

The Phase 1 interim analysis showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. 26, 2020 11:00 UTC. CAMBRIDGE, Mass.–(

Vaccine 52

Vaccine Clinical Development RNA Clinical Trials 52

Codon

JULY 27, 2023

I could write an entire article in response, but if you want to go deeper into this subject, I suggest you read it in full. For a recent study, researchers edited 21 different genes in poplar trees, a species commonly used to make paper. The researchers studied trees with 70,000 different gene-editing combinations, just 0.5%

Therapies 52

Therapies RNA DNA Engineering 52